Joan Albert Barberà Mir-rekin lankidetzan egindako argitalpenak (5)

2023

  1. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

2021

  1. Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension

    Antioxidants, Vol. 10, Núm. 2, pp. 1-14

  2. Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension

    European Respiratory Journal

2020

  1. Total, bioavailable, and free vitamin D levels and their prognostic value in pulmonary arterial hypertension

    Journal of Clinical Medicine, Vol. 9, Núm. 2

2018

  1. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/ perfusion matching

    PLoS ONE, Vol. 13, Núm. 1